FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052608732> ?p ?o ?g. }

• W2052608732 endingPage "1172" @default.
• W2052608732 startingPage "1162" @default.
• W2052608732 abstract "ABSTRACT The aim of this study was to compare the efficacy and safety of tigecycline, a newly developed glycylcycline antibiotic, with those of empirical antibiotic regimens which have been reported to possess good efficacy for complicated skin and skin structure infections (cSSSIs), complicated intra-abdominal infections (cIAIs), community-acquired pneumonia (CAP), and other infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). A meta-analysis of randomized controlled trials (RCTs) identified in PubMed, the Cochrane Library, and Embase was performed. Eight RCTs involving 4,651 patients were included in the meta-analysis. Compared with therapy with empirical antibiotic regimens, tigecycline monotherapy was associated with similar clinical treatment success rates (for the clinically evaluable [CE] population, odds ratio [OR] = 0.92, 95% confidence interval [CI] = 0.76 to 1.12, P = 0.42; for the clinical modified intent-to-treat [c-mITT] population, OR = 0.86, 95% CI = 0.74 to 1.01, P = 0.06) and similar microbiological treatment success rates (for the microbiologically evaluable [ME] population, OR = 0.86, 95% CI = 0.69 to 1.07, P = 0.19). The incidence of adverse events in the tigecycline group was significantly higher than that in the other therapy groups with a statistical margin (for the modified intent-to-treat [mITT] population, OR = 1.33, 95% CI = 1.17 to 1.52, P < 0.0001), especially in the digestive system (mITT population, OR = 2.41, 95% CI = 1.67 to 3.46, P < 0.00001). No difference regarding all-cause mortality and drug-related mortality between tigecycline and the other regimens was found, although numerically higher mortality was found in the tigecycline group. This meta-analysis provides evidence that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE. However, because of the high risk of mortality, AEs, and emergence of resistant isolates, prudence with the clinical use of tigecycline monotherapy in infections is required." @default.
• W2052608732 created "2016-06-24" @default.
• W2052608732 creator A5029906760 @default.
• W2052608732 creator A5035280226 @default.
• W2052608732 creator A5070537920 @default.
• W2052608732 creator A5070812231 @default.
• W2052608732 creator A5073378602 @default.
• W2052608732 date "2011-03-01" @default.
• W2052608732 modified "2023-10-11" @default.
• W2052608732 title "Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease" @default.
• W2052608732 cites W1522563507 @default.
• W2052608732 cites W1965979675 @default.
• W2052608732 cites W1970548642 @default.
• W2052608732 cites W1981565772 @default.
• W2052608732 cites W1986215651 @default.
• W2052608732 cites W1986829760 @default.
• W2052608732 cites W1999311088 @default.
• W2052608732 cites W2001555823 @default.
• W2052608732 cites W2004173277 @default.
• W2052608732 cites W2008399938 @default.
• W2052608732 cites W2009835131 @default.
• W2052608732 cites W2011770881 @default.
• W2052608732 cites W2013205836 @default.
• W2052608732 cites W2023287527 @default.
• W2052608732 cites W2036381816 @default.
• W2052608732 cites W2036740 @default.
• W2052608732 cites W2041797411 @default.
• W2052608732 cites W2046583637 @default.
• W2052608732 cites W2055937325 @default.
• W2052608732 cites W2058674585 @default.
• W2052608732 cites W2078824170 @default.
• W2052608732 cites W2081320515 @default.
• W2052608732 cites W2083794516 @default.
• W2052608732 cites W2087470294 @default.
• W2052608732 cites W2101570801 @default.
• W2052608732 cites W2101847043 @default.
• W2052608732 cites W2107843718 @default.
• W2052608732 cites W2107932739 @default.
• W2052608732 cites W2115889719 @default.
• W2052608732 cites W2122000720 @default.
• W2052608732 cites W2126454691 @default.
• W2052608732 cites W2129261282 @default.
• W2052608732 cites W2130634210 @default.
• W2052608732 cites W2134957876 @default.
• W2052608732 cites W2137217706 @default.
• W2052608732 cites W2141617342 @default.
• W2052608732 cites W2142980821 @default.
• W2052608732 cites W2146844783 @default.
• W2052608732 cites W2153032236 @default.
• W2052608732 cites W2154159203 @default.
• W2052608732 cites W2155301516 @default.
• W2052608732 cites W2159005358 @default.
• W2052608732 cites W2169008501 @default.
• W2052608732 cites W4247752557 @default.
• W2052608732 cites W4254364509 @default.
• W2052608732 doi "https://doi.org/10.1128/aac.01402-10" @default.
• W2052608732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3067123" @default.
• W2052608732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21173186" @default.
• W2052608732 hasPublicationYear "2011" @default.
• W2052608732 type Work @default.
• W2052608732 sameAs 2052608732 @default.
• W2052608732 citedByCount "177" @default.
• W2052608732 countsByYear W20526087322012 @default.
• W2052608732 countsByYear W20526087322013 @default.
• W2052608732 countsByYear W20526087322014 @default.
• W2052608732 countsByYear W20526087322015 @default.
• W2052608732 countsByYear W20526087322016 @default.
• W2052608732 countsByYear W20526087322017 @default.
• W2052608732 countsByYear W20526087322018 @default.
• W2052608732 countsByYear W20526087322019 @default.
• W2052608732 countsByYear W20526087322020 @default.
• W2052608732 countsByYear W20526087322021 @default.
• W2052608732 countsByYear W20526087322022 @default.
• W2052608732 countsByYear W20526087322023 @default.
• W2052608732 crossrefType "journal-article" @default.
• W2052608732 hasAuthorship W2052608732A5029906760 @default.
• W2052608732 hasAuthorship W2052608732A5035280226 @default.
• W2052608732 hasAuthorship W2052608732A5070537920 @default.
• W2052608732 hasAuthorship W2052608732A5070812231 @default.
• W2052608732 hasAuthorship W2052608732A5073378602 @default.
• W2052608732 hasBestOaLocation W20526087321 @default.
• W2052608732 hasConcept C126322002 @default.
• W2052608732 hasConcept C141071460 @default.
• W2052608732 hasConcept C156957248 @default.
• W2052608732 hasConcept C168563851 @default.
• W2052608732 hasConcept C197934379 @default.
• W2052608732 hasConcept C2777027569 @default.
• W2052608732 hasConcept C2908647359 @default.
• W2052608732 hasConcept C44249647 @default.
• W2052608732 hasConcept C501593827 @default.
• W2052608732 hasConcept C71924100 @default.
• W2052608732 hasConcept C86803240 @default.
• W2052608732 hasConcept C89423630 @default.
• W2052608732 hasConcept C95190672 @default.
• W2052608732 hasConcept C99454951 @default.
• W2052608732 hasConceptScore W2052608732C126322002 @default.
• W2052608732 hasConceptScore W2052608732C141071460 @default.
• W2052608732 hasConceptScore W2052608732C156957248 @default.

• next